The Federal Trade Commission (FTC) has filed a legal complaint accusing the 3 largest pharmacy benefit managers (PBMs) in the US—Caremark, Express Scripts, and Optum Rx—of inflating insulin ...

Sanofi announced last year that it was joining other drug companies to set a cap on insulin at $35. The new pricing went into effect on Jan. 1, CNN reported. Sanofi makes Lantus and had already ...

GoodRx, a resource for healthcare savings and information, is working with Sanofi, a company that specializes in diabetes care, to offer people living with diabetes access to Lantus (insulin ...

GoodRx, Sanofi partner on $35 insulin It’s unclear how much the partnership will improve access to affordable insulin given other recent initiatives from drugmakers and public insurance programs.

Telehealth platform GoodRx has become the latest company to offer people with diabetes access to insulin for $35 per month— regardless of whether they have insurance. GoodRx said in a statement ...

The GoodRx announcement comes more than six months after Sanofi pledged to slash the list price of Lantus, establishing a $35 cap on out-of-pocket costs for patients living with diabetes.